GlassScriptPhysician profile
Deron Sharpe
NPI 1104913235
$8,256.40
in general payments reported to CMS, 2019-2025
45 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $468 · 2021: $987 · 2022: $1,405 · 2023: $1,446 · 2024: $1,796 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.49 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,433.01 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $800.25 | 2019-2025 | |
| Eisai INC. | $641.12 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $374.40 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $336.82 | 2023-2025 | Daybue |
| Greenwich Biosciences, INC. | $282.30 | 2019-2021 | |
| Immedica Pharma US, INC. | $268.18 | 2022-2025 | Ztalmy |
| Catalyst Pharmaceuticals, INC. | $224.91 | 2023-2025 | Fycompa |
| Ns Pharma, INC. | $206.05 | 2023-2025 | Viltepso |
| Qol Medical, LLC | $197.69 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $186.11 | 2022-2024 | Xeomin |
| Biogen, INC. | $169.88 | 2022-2024 | Spinraza |
| Livanova USA, INC. | $158.65 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $153.20 | 2023-2025 | Botox |
| Dexcom, INC. | $145.16 | 2021-2024 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deron Sharpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.